Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nikethamide is a central nervous system and respiratory stimulant, historically classified as an analeptic. It functions by stimulating chemoreceptors in the carotid and aortic bodies, which increases the rate and depth of respiration by enhancing the sensitivity of the medullary respiratory center to carbon dioxide. While it was once widely used to treat acute respiratory depression resulting from anesthetic or sedative overdoses, its clinical utility has diminished with the advent of mechanical ventilation and more targeted antagonists. It is currently listed as a prohibited substance by the World Anti-Doping Agency (WADA) due to its potential for performance enhancement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nikethamide.